Using the light, LuViva scans the cervix and identifies cancer and pre-cancer painlessly and non-invasively.

LuViva utilizes the company’s patented biophotonic technology and detects changes at the cellular level, thus helps in distinguishing between normal and diseased tissue.

Guided Therapeutics CEO and president Mark Faupel said they believe that Eurosurgical is ideally positioned to propel LuViva to become the gold standard of care for cervical disease detection in the UK.

Eurosurgical chairman George Cranstone said they believe LuViva will be an excellent addition to their gynaecology product offerings.